Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04045028
Title A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

B-cell lymphoma

multiple myeloma

non-Hodgkin lymphoma

Therapies

Tiragolumab

Daratumumab + Tiragolumab

Rituximab + Tiragolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.